A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy

Cetuximab in combination with an irinotecan‐containing regimen is a standard treatment in patients with KRAS wild‐type (KRAS WT), metastatic colorectal cancer (mCRC). We investigated the addition of the oral MET inhibitor tivantinib to cetuximab + irinotecan (CETIRI) based on preclinical evidence th...

Descripción completa

Detalles Bibliográficos
Autores principales: Eng, Cathy, Bessudo, Alberto, Hart, Lowell L., Severtsev, Aleksey, Gladkov, Oleg, Müller, Lothar, Kopp, Mikhail V., Vladimirov, Vladimir, Langdon, Robert, Kotiv, Bogdan, Barni, Sandro, Hsu, Ching, Bolotin, Ellen, von Roemeling, Reinhard, Schwartz, Brian, Bendell, Johanna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071720/
https://www.ncbi.nlm.nih.gov/pubmed/26891420
http://dx.doi.org/10.1002/ijc.30049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071720/
https://www.ncbi.nlm.nih.gov/pubmed/26891420
http://dx.doi.org/10.1002/ijc.30049

Ejemplares similares